Literature DB >> 21565670

Glucocorticoid-remediable aldosteronism.

Florencia Halperin1, Robert G Dluhy.   

Abstract

Glucocorticoid-remediable aldosteronism (GRA) is a hereditary form of primary hyperaldosteronism and the most common monogenic cause of hypertension. A chimeric gene duplication leads to ectopic aldosterone synthase activity in the cortisol-producing zona fasciculata of the adrenal cortex, under the regulation of adrenocorticotropin (ACTH). Hypertension typically develops in childhood, and may be refractory to standard therapies. Hypokalemia is uncommon in the absence of treatment with diuretics. The discovery of the genetic basis of the disorder has permitted the development of accurate diagnostic testing. Glucocorticoid suppression of ACTH is the mainstay of treatment; alternative treatments include mineralocorticoid receptor antagonists.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565670     DOI: 10.1016/j.ecl.2011.01.012

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  10 in total

Review 1.  Genetics of primary aldosteronism.

Authors:  Anand Vaidya; Amir H Hamrahian; Richard J Auchus
Journal:  Endocr Pract       Date:  2015-02-09       Impact factor: 3.443

2.  A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension.

Authors:  Evangelia Charmandari; Amalia Sertedaki; Tomoshige Kino; Christina Merakou; Dax A Hoffman; Michael M Hatch; Darrell E Hurt; Lin Lin; Paraskevi Xekouki; Constantine A Stratakis; George P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2012-05-24       Impact factor: 5.958

3.  Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion.

Authors:  Amalia Sertedaki; Athina Markou; Dimitrios Vlachakis; Sophia Kossida; Emilie Campanac; Dax A Hoffman; Maria De La Luz Sierra; Paraskevi Xekouki; Constantine A Stratakis; Gregory Kaltsas; George P Piaditis; George P Chrousos; Evangelia Charmandari
Journal:  Clin Endocrinol (Oxf)       Date:  2016-07-12       Impact factor: 3.478

4.  Pediatric endocrine hypertension.

Authors:  Nisha Bhavani
Journal:  Indian J Endocrinol Metab       Date:  2011-10

5.  Role of endogenous ACTH on circadian aldosterone rhythm in patients with primary aldosteronism.

Authors:  Takuhiro Sonoyama; Masakatsu Sone; Naohisa Tamura; Kyoko Honda; Daisuke Taura; Katsutoshi Kojima; Yorihide Fukuda; Naotetsu Kanamoto; Masako Miura; Akihiro Yasoda; Hiroshi Arai; Hiroshi Itoh; Kazuwa Nakao
Journal:  Endocr Connect       Date:  2014-12       Impact factor: 3.335

Review 6.  Genetic Programming of Hypertension.

Authors:  Sun-Young Ahn; Charu Gupta
Journal:  Front Pediatr       Date:  2018-01-22       Impact factor: 3.418

Review 7.  Role of environmental toxicants in the development of hypertensive and cardiovascular diseases.

Authors:  Ehsan Habeeb; Saad Aldosari; Shakil A Saghir; Mariam Cheema; Tahani Momenah; Kazim Husain; Yadollah Omidi; Syed A A Rizvi; Muhammad Akram; Rais A Ansari
Journal:  Toxicol Rep       Date:  2022-03-22

8.  Primary hyperaldosteronism: challenges in subtype classification.

Authors:  Brian T Layden; Allison J Hahr; Dina M Elaraj
Journal:  BMC Res Notes       Date:  2012-10-30

9.  Different effects of progesterone and estradiol on chimeric and wild type aldosterone synthase in vitro.

Authors:  Andrea Vecchiola; Carlos F Lagos; Cristóbal A Fuentes; Fidel Allende; Carmen Campino; Carolina Valdivia; Alejandra Tapia-Castillo; Tadashi Ogishima; Kuniaki Mukai; Gareth Owen; Sandra Solari; Cristian A Carvajal; Carlos E Fardella
Journal:  Reprod Biol Endocrinol       Date:  2013-08-13       Impact factor: 5.211

10.  A Case of Glucocorticoid Remediable Aldosteronism and Thoracoabdominal Aneurysms.

Authors:  Anahita Shahrrava; Sunnan Moinuddin; Prajwal Boddu; Rohan Shah
Journal:  Case Rep Endocrinol       Date:  2016-06-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.